Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.

Zhang T, Forde PM, Sullivan RJ, Sharon E, Barksdale E, Selig W, Ebbinghaus S, Fusaro G, Gunenc D, Battle D, Burns R, Hurlbert MS, Stewart M, Atkins MB

Open source

DOI: 10.1136/jitc-2022-006555
Published: 2023 May
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-006555,
  title = {Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.},
  author = {Zhang T and Forde PM and Sullivan RJ and Sharon E and Barksdale E and Selig W and Ebbinghaus S and Fusaro G and Gunenc D and Battle D and Burns R and Hurlbert MS and Stewart M and Atkins MB},
  year = {2023},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-006555},
  url = {https://doi.org/10.1136/jitc-2022-006555}
}

RIS

TY  - JOUR
TI  - Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
AU  - Zhang T
AU  - Forde PM
AU  - Sullivan RJ
AU  - Sharon E
AU  - Barksdale E
AU  - Selig W
AU  - Ebbinghaus S
AU  - Fusaro G
AU  - Gunenc D
AU  - Battle D
AU  - Burns R
AU  - Hurlbert MS
AU  - Stewart M
AU  - Atkins MB
PY  - 2023
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-006555
UR  - https://doi.org/10.1136/jitc-2022-006555
ER  -

APA

T, Z., PM, F., RJ, S., E, S., E, B., W, S., S, E., G, F., D, G., D, B., R, B., MS, H., M, S., & MB, A. (2023). Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-006555

Source records

pubmed · retrieved 2026-09-26T12:02:48.621Z